Medical Marijuana Inc. jumps to net income in Q2 2019, from loss in Q2 last year

Medical Marijuana, the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, record revenue of $20.7 million in the second quarter of 2019, a 30.8% increase over the same quarter in 2018.

Read more

Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity – two common nerve agents

Nexien BioPharma was granted patent for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.

Read more

EMMAC Life Sciences partner with Hyris to develop Unique Real-Time Phyto-Cannabinoid Rich technology for the specific identification of proprietary cultivars of Cannabis subsp.

EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company, to develop a comprehensive library of genetic profiles of existing cannabis varieties, and to industrialise DNA-based methods for the identification of its unique branded cultivars.

Read more